HLN Stock Analysis: Buy, Sell, or Hold?
HLN - Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$8.72
0.02 (0.23%)
▲
5d:
-6.44%
30d:
-5.63%
90d:
-16.71%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When HLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HLN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.42
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$8.96
2.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HLN is currently trading at $8.72, which is considered oversold relative to its 30-day fair value range of $8.96 to $9.36. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.3) compared to its historical average (17.1). Remarkably, the market is currently pricing in an annual earnings decline of 5.8% over the next few years. This pessimistic expectation contrasts with the company's recent 92.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $8.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HLN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.74 (+34.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HLN is in a strong downtrend. The price is currently testing key support at $8.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HLN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.74 (+34.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.96 -
$9.36
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.6% below Wall St target ($11.74)
- CAUTION: 5-day price weakness (-6.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$8.96 -
$9.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$8.65
Resistance Level
$9.39
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.29
Wall Street Target
$11.74
(+34.6%)
Revenue Growth (YoY)
0.6%
Earnings Growth (YoY)
92.0%
Profit Margin
15.1%
Valuation Discount vs History
-5.8% cheaper
PE vs Historical
14.3 vs 17.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.8%
(market-implied from PE analysis)
1-Year Target
$8.21
(-6%)
2-Year Target
$7.74
(-11%)
3-Year Target
$7.29
(-16%)
3-Yr Target (if PE normalizes)
(PE: 14→17)
$8.72
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 9.4%)
$17.52
(+101%)
Base:
(SPY PE: 14.3, Growth: 9.4%)
$11.42
(+31%)
Bear:
(PE: 12.1, Growth: 9.4%)
$9.71
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 18.64 | Current EPS (TTM): $0.50
Bull Case
$12.52
(+36%)
Analyst growth 22.1%, PE expands to 20.5
Base Case
$11.38
(+24%)
Market implied 22.1%, PE stable at 18.6
Bear Case
$6.34
(-31%)
Severe decline -20.0%, PE contracts to 15.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.3 to 17.1
Stabilization Target:
$10.44
(+19.7%)
PE Expansion Potential:
+19.7%
Share & Embed Analysis
Last updated: June 03, 2026 8:06 PM ET
Data refreshes hourly during market hours. Next update: 9:06 PM
Data refreshes hourly during market hours. Next update: 9:06 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
